Literature DB >> 7311638

Screening for noncompliance among patients with hypertension: is self-report the best available measure?

T S Inui, W B Carter, R E Pecoraro.   

Abstract

The substantial prevalence of noncompliance with drugs in populations of patients with treated hypertension suggests that a reliable, clinically applicable screening test for this behavior is needed. Among employed white males, patient response to a nonjudgmental clinician inquiry has been reported to be highly predictive of noncompliance when positive but relatively insensitive (40 per cent). We assessed the performance of patient self-report in a demographically different population and confirmed the generalizability of prior observations. A compound decision rule combining blood pressure and verbal inquiry observations, however, had higher sensitivity (83 per cent) for noncompliance in our population than self-report alone (55 per cent) and could be considered for use when the prevalence of noncompliance among uncontrolled hypertensives is sufficiently high. Because 40 per cent of well-controlled hypertensives in our test population were noncompliant by pill-count, a question is raised regarding the need for "stepping down" drug therapy in some individuals under treatment for high blood pressure.

Entities:  

Mesh:

Year:  1981        PMID: 7311638     DOI: 10.1097/00005650-198110000-00008

Source DB:  PubMed          Journal:  Med Care        ISSN: 0025-7079            Impact factor:   2.983


  27 in total

Review 1.  Selective versus nonselective beta adrenoceptor antagonists in hypertension.

Authors:  L M Van Bortel; A J Ament
Journal:  Pharmacoeconomics       Date:  1995-12       Impact factor: 4.981

Review 2.  Using patients' descriptions of alcohol consumption, diet, medication compliance, and cigarette smoking: the validity of self-reports in research and practice.

Authors:  V J Strecher; M H Becker; N M Clark; P Prasada-Rao
Journal:  J Gen Intern Med       Date:  1989 Mar-Apr       Impact factor: 5.128

3.  Obesity Modifies the Association of Race/Ethnicity with Medication Adherence in the CARDIA Study.

Authors:  Maribel Salas; Catarina I Kiefe; Pamela J Schreiner; Yongin Kim; Lucia Juarez; Sharina D Person; O Dale Williams
Journal:  Patient       Date:  2008-01-01       Impact factor: 3.883

4.  Medication nonadherence and subsequent risk of hospitalisation and mortality among older adults.

Authors:  Shelly A Vik; David B Hogan; Scott B Patten; Jeffrey A Johnson; Lori Romonko-Slack; Colleen J Maxwell
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

5.  Are two commonly used self-report questionnaires useful for identifying antihypertensive medication nonadherence?

Authors:  Benjamin D Gallagher; Paul Muntner; Nathalie Moise; Jenny J Lin; Ian M Kronish
Journal:  J Hypertens       Date:  2015-05       Impact factor: 4.844

6.  Measurement of patient compliance.

Authors:  A H Paes; A Bakker; C J Soe-Agnie
Journal:  Pharm World Sci       Date:  1998-04

Review 7.  What do you do when the blood pressure is up? An approach to the known hypertensive who has an elevated blood pressure.

Authors:  R L Schiff; M H Cohen; A Balson
Journal:  J Gen Intern Med       Date:  1991 Jan-Feb       Impact factor: 5.128

8.  Asthma and the home environment of low-income urban children: preliminary findings from the Seattle-King County healthy homes project.

Authors:  J W Krieger; L Song; T K Takaro; J Stout
Journal:  J Urban Health       Date:  2000-03       Impact factor: 3.671

9.  Effects of computerized guidelines for managing heart disease in primary care.

Authors:  William M Tierney; J Marc Overhage; Michael D Murray; Lisa E Harris; Xiao-Hua Zhou; George J Eckert; Faye E Smith; Nancy Nienaber; Clement J McDonald; Fredric D Wolinsky
Journal:  J Gen Intern Med       Date:  2003-12       Impact factor: 5.128

10.  Clinical evaluation of IDAS II, a new electronic device enabling drug adherence monitoring.

Authors:  Valérie Santschi; Grégoire Wuerzner; Marie-Paule Schneider; Olivier Bugnon; Michel Burnier
Journal:  Eur J Clin Pharmacol       Date:  2007-09-25       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.